Inactive Instrument

LYSOGENE

LYS

FR0013233475

Biotechnology & Medical Research

Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index

July 06, 2023 at 12:00 am EDT

Lysogene S.A. has been dropped from Next Biotech Index.

Latest news about LYSOGENE

Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	23-07-06	CI
Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	23-07-06	CI
Lysogene CFO Assumes Same Role at Mauna Kea Technologies	23-06-14	MT
Lysogene: placed in liquidation and delisted	23-05-29	CF
Lysogene to Delist from Euronext amid Judicial Liquidation	23-05-29	MT
Lysogene S.A. Announces Postponement of 2022 Financial Results Release	23-04-29	CI
Lysogene: no takeover bid received for biotech company	23-04-17	CF
Lysogene Fails to Secure Takeover Bid Amid Reorganization	23-04-17	MT
Lysogene: deadline for takeover bids extended	23-03-27	CF
Lysogene: interim CFO confirmed	23-02-06	CF
French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	23-02-06	MT
Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	23-02-03	CI
Lysogene: company placed in receivership	23-01-25	CF
Lysogene: officially looking for a buyer	23-01-09	CF
Lysogene Seeks Launch of Safeguard Process Amid Financing Woes	22-12-07	MT
Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study	22-11-18	CI
Lysogene S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-23	CI
Lysogene Announces New Board of Directors	22-09-16	CI
Lysogene's Gene Therapy Improves Cognitive, Motor Functions In Initial Phase 2/3 Data	22-07-07	MT
Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA	22-07-07	CI
Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting	22-05-18	CI
Lysogene's Gene Therapy Shows Long-Term Rescue of Fragile X Syndrome in Mouse Model	22-04-21	MT
Lysogene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia	22-02-24	CI
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101	22-02-11	CI

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing

LYSOGENE

Equities

LYS

FR0013233475

Biotechnology & Medical Research

Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index

Latest news about LYSOGENE

Chart LYSOGENE

Company Profile

Sector Bio Diagnostics & Testing